Does the ISCHEMIA Trial Apply to My Patients?

Upadhyaya V., Gowda S. N., Porto G., Bavishi C. P., Sardar P., Bashir R., ...More

CURRENT CARDIOLOGY REPORTS, vol.24, no.6, pp.653-657, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 24 Issue: 6
  • Publication Date: 2022
  • Doi Number: 10.1007/s11886-022-01684-7
  • Journal Name: CURRENT CARDIOLOGY REPORTS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.653-657
  • Keywords: Ischemic heart disease, Chest pain, Coronary disease, Antianginal, Revascularization, PERCUTANEOUS CORONARY INTERVENTION, FRACTIONAL FLOW RESERVE, CHRONIC KIDNEY-DISEASE, MYOCARDIAL-INFARCTION, RANDOMIZED-TRIALS, FOLLOW-UP, METAANALYSIS, ANGINA, THERAPY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Purpose of Review The ISCHEMIA trial demonstrated no difference in myocardial infarction or death in patients with stable coronary disease and moderate or large ischemia territory treated either with invasive revascularization or optimal medical therapy. Whether the findings of the randomized control trial relates to real-world outcomes is uncertain. Recent Findings Contemporary guideline-directed medical therapy has had a significant impact on the prognosis of coronary artery disease. Various observational data appear to indicate limited generalizability of the ISCHEMIA trial in different populations. Further studies are warranted to evaluate the optimal modality of therapy in patients with stable coronary disease and moderate or severe ischemia. The applicability of ISCHEMIA and ISCHEMIA-CKD trials still requires further validation.